This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search
Button

Menu

Close

HomeAbout CIBINQODosing & MonitoringDosing & MonitoringDosingStarting & MonitoringEfficacyEfficacy 

Pivotal Trial Results

Monotherapy ResultsCombination Therapy ResultsCombination Therapy in Pediatric Patients 12 to <18 ResultsBefore and After Images

Post-Hoc Analysis Results

Post-Hoc Analysis Results
SafetySafetyImportant Safety ConsiderationsSafety & TolerabilitySavings & SupportSavings & SupportAccessDownloadable Copay Savings CardRequest an eRepEventsMaterialsVideos
 Search
Button

Menu

Close

HomeAboutAbout

Example of description text sitting alongside header

Pfizer JAK InnovationHow CIBINQO WorksIdentifying PatientsAAD 2023 GuidelinesEfficacyEfficacy 

Example of description text sitting alongside header

Study DesignsSkin ClearanceEASI-75 DataIGA 0/1 & EASI-90 DataSkin Clearance at Week 96Post Hoc Analysis ResultsBefore and After PhotosItch ReductionItch Reduction Data (PP-NRS4)Absolute Change From Baseline in PP-NRSSafetySafety

Example of description text sitting alongside header

Important Safety ConsiderationsSafety & TolerabilityDosing & MonitoringDosing & Monitoring

Example of description text sitting alongside header

DosingStarting & MonitoringSavings & SupportSavings & Support

Example of description text sitting alongside header

Patient SupportCost & CoverageDownloadable Copay Savings CardRequest an eRepEventsMaterialsVideos
Prescribing Information, including BOXED WARNINGMedication GuideIndicationPatient SiteInformación de Prescripción Completa
EfficacyBefore and after photos1,2

View EASI-75 data and IGA 0/1 data

RECOMMENDED DOSE: CIBINQO 100 mgIf response is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.

Light

Medium

Dark

Select Baseline, Week 2, and Week 12 to see improvement for patients taking CIBINQOArm

Example

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 45
SEX: Male
TRIAL: MONO-2
IGA AT BASELINE: 4 (Severe)

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 45
SEX: Male
TRIAL: MONO-2

Clinical trial labels have been blurred in photos.

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 45
SEX: Male
TRIAL: MONO-2
IGA AT BASELINE: 4 (Severe)
IGA AT WEEK 12: 2 (Mild)

The patient did not meet the co-primary endpoint for IGA response as defined in the JADE MONO-2 protocol as an achievement of an IGA score of 0 or 1 with a 2-point improvement from baseline at week 12.

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Abdomen

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 28
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)

AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 28
SEX: Female
TRIAL: MONO-2

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 28
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)
IGA AT WEEK 12: 1 (Almost clear)

AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Chest

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 24
SEX: Male
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)

AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 24
SEX: Male
TRIAL: MONO-2

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 24
SEX: Male
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)
IGA AT WEEK 12: 2 (Mild)

The patient did not meet the co-primary endpoint for IGA response as defined in the JADE MONO-2 protocol as an achievement of an IGA score of 0 or 1 with a 2-point improvement from baseline at week 12.

AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Inner elbow

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 24
SEX: Male
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)

AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 24
SEX: Male
TRIAL: MONO-2

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 24
SEX: Male
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)
IGA AT WEEK 12: 2 (Mild)

The patient did not meet the co-primary endpoint for IGA response as defined in the JADE MONO-2 protocol as an achievement of an IGA score of 0 or 1 with a 2-point improvement from baseline at week 12.

AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Shin

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 53
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 53
SEX: Female
TRIAL: MONO-2

Clinical trial labels have been blurred in photos.

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 100 mg
AGE: 53
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 3 (Moderate)
IGA AT WEEK 12: 1 (Almost clear)

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Recommended dose: CIBINQO 100 mg
If response is inadequate after 12 weeks, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
Select Baseline, Week 2, and Week 12 to see improvement for patients taking CIBINQOFace

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

7-day run-in of nonmedicated emollients was required.

DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
IGA AT BASELINE: 4 (Severe)

AD=atopic dermatitis; TCS=topical corticosteroids.

7-day run-in of nonmedicated emollients was required.

DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE

AD=atopic dermatitis; TCS=topical corticosteroids.

7-day run-in of nonmedicated emollients was required.

DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
IGA AT BASELINE: 4 (Severe)
IGA AT WEEK 12: 0 (Clear)

AD=atopic dermatitis; TCS=topical corticosteroids; IGA=Investigator’s Global Assessment.

Lower chest/abdomen

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

7-day run-in of nonmedicated emollients was required.

DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
IGA AT BASELINE: 4 (Severe)

AD=atopic dermatitis; TCS=topical corticosteroids.

7-day run-in of nonmedicated emollients was required.

DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE

AD=atopic dermatitis; TCS=topical corticosteroids.

7-day run-in of nonmedicated emollients was required.

DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
IGA AT BASELINE: 4 (Severe)
IGA AT WEEK 12: 0 (Clear)

AD=atopic dermatitis; TCS=topical corticosteroids; IGA=Investigator’s Global Assessment.

Select Baseline, Week 2, and Week 12 to see improvement for patients taking CIBINQOCalf

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 200 mg
AGE: 43
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 4 (Severe)

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 200 mg
AGE: 43
SEX: Female
TRIAL: MONO-2

Clinical trial labels have been blurred in photos.

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 200 mg
AGE: 43
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 4 (Severe)
IGA AT WEEK 12: 3 (Moderate)

The patient did not meet the co-primary endpoint for IGA response as defined in the JADE MONO-2 protocol as an achievement of an IGA score of 0 or 1 with a 2-point improvement from baseline at week 12.

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Lower leg

Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.

Baseline

Week 2

Week 12

Nonmedicated emollients were allowed.

DOSE: 200 mg
AGE: 43
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 4 (Severe)

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

Nonmedicated emollients were allowed.

DOSE: 200 mg
AGE: 43
SEX: Female
TRIAL: MONO-2

Clinical trial labels have been blurred in photos.

AD=atopic dermatitis.

Nonmedicated emollients were allowed.

DOSE: 200 mg
AGE: 43
SEX: Female
TRIAL: MONO-2
IGA AT BASELINE: 4 (Severe)
IGA AT WEEK 12: 3 (Moderate)

The patient did not meet the co-primary endpoint for IGA response as defined in the JADE MONO-2 protocol as an achievement of an IGA score of 0 or 1 with a 2-point improvement from baseline at week 12.

Clinical trial labels have been blurred in photos.
AD=atopic dermatitis; IGA=Investigator’s Global Assessment.

EASI-75=≥75% improvement in lesion extent and severity from baseline on the Eczema Area and Severity Index; IGA=Investigator’s Global Assessment. Explore more Safety Take a look at the safety information for CIBINQO Go to Safety Loading Meaningful Itch Reduction

See data showing 4-point improvement in PP-NRS at week 2

 Itch Reduction Data LoadingPP-NRS4=≥4-point improvement from baseline on the Peak Pruritus Numerical Rating Scale.References:Data on file. Pfizer Inc; New York, NY.CIBINQO Package insert. Pfizer Inc; 2023.Efficacy Ready to Start Your Patients on CIBINQO?

Resources such as the discussion guide and patient brochure can help

 Explore Resources Loading Connect With a Representative

A product representative is available to help you learn more about CIBINQO

 Get in Touch Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-CIB-USA-0993
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-CIB-USA-0156
INDICATION CIBINQO® (abrocitinib) is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
Important Safety Information WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS SERIOUS INFECTIONS Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death. The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia. If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection. Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions:
  • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test.
  • Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
  • Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens. 
​​​​Avoid use of CIBINQO in patients with an active, serious infection, including localized infections. The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections or those who have resided or traveled in areas of endemic tuberculosis or endemic mycoses. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Consider yearly screening for patients in highly endemic areas for TB. CIBINQO is not recommended for use in patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, or for patients with a negative test for latent TB but who are at high risk for TB infection, start preventive therapy for latent TB prior to initiation of CIBINQO.  Viral reactivation, including herpes virus reactivation (eg, herpes zoster, herpes simplex), was reported in clinical studies with CIBINQO. If a patient develops herpes zoster, consider interrupting CIBINQO until the episode resolves. Hepatitis B virus reactivation has been reported in patients receiving JAK inhibitors. Perform viral hepatitis screening in accordance with clinical guidelines before starting therapy and monitor for reactivation during therapy with CIBINQO. CIBINQO is not recommended for use in patients with active hepatitis B or hepatitis C.MORTALITY
In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality (including sudden cardiovascular death) was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients.MALIGNANCIES
Malignancies, including non-melanoma skin cancer (NMSC), were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions. Perform periodic skin examination for patients who are at increased risk for skin cancer. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. CIBINQO is not approved for use in RA patients. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) 
Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers. CIBINQO is not approved for use in RA patients. Patients who are current or past smokers are at additional increased risk. Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.THROMBOSIS
Deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of overall thrombosis, DVT, and PE were observed when compared with TNF blockers. CIBINQO is not approved for use in RA patients.Avoid CIBINQO in patients that may be at increased risk of thrombosis. If symptoms of thrombosis occur, discontinue CIBINQO and treat patients appropriately.CONTRAINDICATION
CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.LABORATORY ABNORMALITIES
Hematologic Abnormalities: Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia. Prior to CIBINQO initiation, perform a complete blood count (CBC). CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities.Lipid Elevations: Dose-dependent increase in blood lipid parameters were reported in patients treated with CIBINQO. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy, and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.IMMUNIZATIONS
Prior to initiating CIBINQO, complete all age-appropriate vaccinations as recommended by current immunization guidelines, including prophylactic herpes zoster vaccinations. Avoid vaccination with live vaccines immediately prior to, during, and immediately after CIBINQO therapy.RENAL IMPAIRMENT
Avoid use in patients with severe renal impairment or end stage renal disease, including those on renal replacement therapy.HEPATIC IMPAIRMENT
Avoid use in patients with severe hepatic impairment.ADVERSE REACTIONS
Most common adverse reactions (≥1% with CIBINQO 100 mg) are nasopharyngitis, nausea, headache, herpes simplex, increased blood creatine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, impetigo, oropharyngeal pain, hypertension, influenza, gastroenteritis, and dermatitis contact.Most common adverse reactions (≥1% with CIBINQO 200 mg and greater than CIBINQO 100 mg) are nausea, headache, herpes simplex, increased blood creatine kinase, dizziness, urinary tract infection, acne, vomiting, gastroenteritis, upper abdominal pain, abdominal discomfort, herpes zoster, and thrombocytopenia.Inform patients that retinal detachment has been reported in CIBINQO clinical trials. Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision.DRUG INTERACTIONS
Monitor appropriately or dose titrate P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities when coadministered with CIBINQO. See Prescribing Information for clinically relevant drug interactions.USE IN PREGNANCY
Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Advise patients who can become pregnant that CIBINQO may impair fertility.There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770 or visit CIBINQOPregnancyRegistry.com. LACTATION
Advise patients not to breastfeed during treatment with CIBINQO and for one day after the last dose.Please see full Prescribing Information, including BOXED WARNING, and Medication Guide. INDICATIONCIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.